Copyright ©2026 Penumbra, Inc. All rights reserved. Copyright ©2026 Penumbra, Inc. All rights reserved. 2 Copyright ©2026 Penumbra, Inc. All rights reserved. 3 Copyright ©2026 Penumbra, Inc. All rights reserved. 4 Copyright ©2026 Penumbra, Inc. All rights reserved. 5 | Arterial | Venous / DVT | PE | Coronary | Stroke | | --- | --- | --- | --- | --- | | Patients2 | Patients® | Patients' | Patients® | Patients® | | 259K | 351K | 157 K | 239K | 200K | Copyright ©2026 Penumbra, Inc. All rights reserved. 6 Copyr ...

Transforming how better health happens J.P. Morgan Healthcare Conference January 2026 Safe Harbor This presentation contains, and the officers of Teladoc Health, Inc. (the "Company" or "Teladoc Health") may make, "forward-looking" statements that are based on management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, information concerning possible or assumed future results of operations, including descriptions of ...

Establishing the New Standard of Care for Organ Transplantation Waleed Hassanein, MD President & CEO January 2026 Cautionary Note Regarding Forward Looking Statements This presentation contains forward-looking statements. These forward-looking statements address various matters, including, among other things, future results and events, including growth initiatives and strategies, including potential timelines for products, services, and future product and services candidates, and those relating to the compa ...

J.P. Morgan 44th Annual Healthcare Conference Pat J. Beyer President and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer January 12th, 2026 Forward-Looking Information This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous dis ...

Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events, progress, timing or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including stateme ...

Financial Performance & Guidance - BRINSUPRI achieved preliminary unaudited U S net revenues of approximately $144 6 million in Q4 2025 and $172 7 million for the full year 2025[23] - ARIKAYCE generated worldwide revenue of approximately $433 8 million in FY 2025, representing a 19 3% increase year-over-year[27] - The company anticipates ARIKAYCE revenue to be between $450 million and $470 million for the full year 2026[28] Clinical Development Programs - The company expects topline data readout from the Phase 3 ENCORE trial for ARIKAYCE in March/April 2026, potentially leading to label expansion[30, 31] - Phase 3 trials for TPIP in PAH, PPF, and IPF are expected to initiate in early and the second half of 2026 respectively[13, 38] - Topline data readout from the Phase 2 CEDAR trial for brensocatib in Hidradenitis Suppurativa is expected in Q2 2026[46, 50] Pipeline Expansion - The company plans to file Investigational New Drug (IND) applications for RA and IBD in the second half of 2026[13, 50] - IND filing for Stargardt is anticipated in 2026[13, 59] - Phase 2 programs in ILD and moderate to severe asthma are planned for INS1148[13, 40] Commercial Expansion - BRINSUPRI is expected to launch in the EU and UK, pending regulatory approval[13, 44] - BRINSUPRI is also anticipated to launch in Japan, pending regulatory approval[13, 44] Cash Position - The company reported a cash position of $1 7 billion as of September 30, 2025[62]

Financial Performance & Strategy - Astellas' FY25 sales revenue reached ¥2 trillion[8] - Core operating profit margin for FY25 was 20.5%[7, 8] - The company aims to elevate profitability and invest in strategic brands and pipeline[14] - Astellas is implementing a disciplined cost optimization plan targeting ¥150 billion ($1.03 billion) in savings between FY24-27[46, 47] R&D and Pipeline - R&D expenses represent 17% of revenue[8] - The company is progressing R&D pipelines in synergy with Strategic Brands[20] - ASP3082 (setidegrasib) + mFOLFIRINOX shows objective responses in PDAC patients with KRAS G12D mutations, with an ORR of 58.3% (7/12) and a DCR of 83.3% (10/12)[35, 37] - ASP2138 in combination with Standard of Care drives striking anti-tumor activity in Gastric/GEJ adenocarcinoma irrespective of Claudin 18.2 Expression, with an ORR of 62.5% (15/24) and a 12-week DCR of 100.0% (6/6)[42, 45] Key Products & Market Access - Over 172 million patients in >70 countries are reached by Astellas products[8] - >1,300,000 men (FY2012-2024) treated globally with XTANDI[10]

If You Didn't Buy Roivant in 2025, Now Is the Time J.P. Morgan Healthcare Conference January 12, 2026 Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial p ...

Financial Performance & Growth - The company projects total revenue of $11.9-12 billion in 2026[37] - Approximately $1.9 billion was deployed through Q3 2025 for share repurchases, buying back around 4.5 million shares[37] - The company exceeded its goal with CASGEVY revenue reaching $100 million in FY 2025[18] Cystic Fibrosis (CF) Portfolio - The company's CF medicines have the potential to treat approximately 95% of people with CF[16] - CF population average annual growth rate is approximately 3% from 2020-2025[17] - The company's CF portfolio has patent protection through approximately 2040[13] Emerging Renal Franchise - The company completed engagement with over 60 payers representing approximately 190 million covered lives in 2025[30] - Povetacicept in IgAN targets a patient population of approximately 330,000 in the US and Europe, and over 1.5 million globally[31] - Inaxaplin targets approximately 250,000 patients with APOL1-mediated kidney disease (AMKD)[11] Pain Management - The company is targeting over 3x prescription growth for JOURNAVX compared to 2025[22] - JOURNAVX is part of multimodal therapy for acute pain following aesthetic and reconstructive procedures, 90.9% of patients were rescue opioid-free through end of treatment[24]

44th Annual J.P. Morgan Healthcare Conference Andrew Hider President & Chief Executive Officer January 12, 2026 1 Safe Harbor Statement This presentation includes forward-looking statements concerning the company's financial results (including the company's net leverage target and estimated timing considerations) and operational, business development and regulatory activities. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause a ...